Search
Lazertinib
go.drugbank.com/drugs/DB16216ApprovedInvestigationalLazertinib is an oral, third-generation, epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI). … [A264289] It was approved by the FDA on August 19, 2024.[L51189] Lazertinib is used alone or in combination with other chemotherapeutic agents.[L51184]
Golimumab
go.drugbank.com/drugs/DB06674ApprovedInvestigationalThus golimumab is indicated for use in adults (i) as an adjunct to methotrexate treatment in patients with moderate to severe active rheumatoid arthritis (RA), (ii) alone or as an adjunct to methotrexate … with active psoriatic arthritis (PsA), (iii) as a single agent in patients with active ankylosing spondylitis (AS), and (iv) as a single agent in patients with moderate to severe ulcerative colitis (UC
Trihexyphenidyl
go.drugbank.com/drugs/DB00376ApprovedInvestigational[L31843] It has largely been replaced by drugs such as [levodopa].[L31843] Trihexyphenidyl was granted FDA approval on 13 May 1949.[L31768]
Citalopram
go.drugbank.com/drugs/DB00215ApprovedInvestigational[A261316] Citalopram was approved by the FDA in 1998 for the treatment of depression in adults 18 years or older.[L5230] … Citalopram is an antidepressant belonging to the class of selective _serotonin-reuptake inhibitors_ (SSRIs) widely used to treat the symptoms of depression.
Products: Ran-citalo, Ran-citalopramHexylcaine
go.drugbank.com/drugs/DB00473ApprovedWithdrawnHexylcaine has been discontinued in the US market. … Patients experience an overdose may present with headache, tinnitus, numbness and tingling around the mouth and tongue, convulsions, inability to breathe, and decreased heart function.
Talquetamab
go.drugbank.com/drugs/DB16678ApprovedInvestigationalIt consists of two arms - anti-GPRC5D and anti-CD3 arms - linked by two interchain disulfide bonds, each arm comprising a heavy and light chain. … [L47775] Talquetamab was fully approved by the EMA on August 22, 2023.[L48822] On August 9, 2023, talquetamab was granted FDA accelerated approval.[L47770]
Synonyms: SAPIENS GPRC5D (G PROTEIN-COUPLED RECEPTOR CLASS C GROUP 5 MEMBER D)), AND ANTI-(HOMO SAPIENS CD3E (CD3 EPSILON, LEU-4)), HUMANIZED AND CHIMERIC MONOCLONAL ANTIBODY; BISPECIFIC GAMMA4 HEAVY CHAIN HUMANIZED ANYellow fever vaccine
go.drugbank.com/drugs/DB10805ApprovedInvestigationalYellow fever vaccine prevents against Yellow Fever, a viral hemorrhagic disease caused by the transmission of a _flavivirus_ through the bite of an infected mosquito. … Symptoms of Yellow fever can range from asymptomatic, to mild flu-like illness, to more severe symptoms such as shock, jaundice, internal bleeding, and organ failure [L1655].
Choline
go.drugbank.com/drugs/DB00122ApprovedInvestigationalNutraceuticalA basic constituent of lecithin that is found in many plants and animal organs. It is important as a precursor of acetylcholine, as a methyl donor in various metabolic processes, and in lipid metabolism.
Mixtures: New Chapter's D'adamo 4 Your Type Multiple for Type O, Phytovim CapDuvelisib
go.drugbank.com/drugs/DB11952ApprovedInvestigationalDuvelisib, also known as IPI-145 and INK-1197, is a small-molecule inhibitor of phosphoinositide-3 kinases that was designed initially to prove that simultaneous inhibition of the isoforms delta and gamma can … [A39025] Duvelisib was developed by Verastem, Inc and FDA approved on September 24, 2018.[L4585]
Diltiazem
go.drugbank.com/drugs/DB00343ApprovedInvestigationalIt works through various mechanisms of action, but it primarily works by inhibiting the calcium influx into cardiac and vascular smooth muscle during depolarization. … Approved in 1982 by the FDA, it is a member of the non-dihydropyridine calcium channel blockers drug class.